Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study - Quiz - MDSpire

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • By

  • Carlyn Rose Tan

  • Sireesha Asoori

  • Chiung-Yu Huang

  • Larissa Brunaldi

  • Rakesh Popat

  • Efstathios Kastritis

  • Joaquin Martinez-Lopez

  • Radhika Bansal

  • Andre De Menezes Silva Corraes

  • Saurabh Chhabra

  • Ricardo Parrondo

  • Sikander Ailawadhi

  • Despina Fotiou

  • Meletios A. Dimopoulos

  • Kwee Yong

  • Catriona Mactier

  • Chris Lau

  • Magdalena Corona

  • Adolfo Jesús Sáez Marin

  • Hira Mian

  • Brian GM. Durie

  • Saad Z. Usmani

  • Thomas G. Martin

  • Yi Lin

  • April 3, 2025

  • 0 min

Share

Original Source(s)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • by Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A. Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Jesús Sáez Marin, Hira Mian, Brian GM. Durie, Saad Z. Usmani, Thomas G. Martin, Yi Lin

  • April 3, 2025

Related Content

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders